Sunitinib – vom Paradigmenwechsel zu einem Therapiestandard beim metastasierten Nierenzellkarzinom (mRCC)

Publisher： Karger

E-ISSN： 2296-5262|33|1|2-4

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.33, Iss.1, 2010-01, pp. : 2-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sunitinib im klinischen Alltag: Das Expanded-Access-Programm beim metastasierten Nierenzellkarzinom

By  

Oncology Research and Treatment, Vol. 33, Iss. 1, 2010-01 ,pp. : 12-14

Karger

Access to resources Recommend Favorite

Erstlinientherapie des metastasierten Nierenzellkarzinoms (mRCC) – Update 2009

By  

Oncology Research and Treatment, Vol. 33, Iss. 1, 2010-01 ,pp. : 5-9

Karger

Access to resources Recommend Favorite

ASCO 2010: Stellenwert von Sunitinib und Temsirolimus bestätigt mRCC-Patienten profitieren vonLangzeittherapie mit Sunitinib

By  

Oncology Research and Treatment, Vol. 33, Iss. 8-9, 2010-09 ,pp. : 483-483

Karger

Access to resources Recommend Favorite

Efficacy of Sunitinib Re-Exposure after Failure of an mTOR Inhibitor in Patients with Metastatic RCC

By  

Oncology Research and Treatment, Vol. 34, Iss. 6, 2011-05 ,pp. : 310-314

Karger

Access to resources Recommend Favorite

Neue Therapiestrategie beim Nierenzellkarzinom und GIST wirksam

By  

Oncology Research and Treatment, Vol. 30, Iss. 1-2, 2007-01 ,pp. : 74-75

Karger

Access to resources Recommend Favorite